Recipharm Builds Global Scale With Kemwell Buy
This article was originally published in Scrip
Recipharm AB is acquiring Kemwell's pharmaceutical contract development and manufacturing (CDMO) businesses for about SEK1.7bn ($206m) – a transaction that will give the Swedish firm an operational presence in the US and also builds on its position in emerging markets.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.